Dopamine D1 receptor antagonists - Pipeline Insight, 2024

Dopamine D1 receptor antagonists - Pipeline Insight, 2024

DelveInsight’s, “Dopamine D1 Receptor Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Dopamine D1 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dopamine D1 Receptor Antagonists Understanding

Dopamine D1 Receptor Antagonists: Overview

Dopamine receptor D1, also known as DRD1, is a protein that in humans is encoded by the DRD1 gene. D1 receptors are the most abundant kind of dopamine receptor in the central nervous system.

Function - D1 receptors regulate the growth of neurons, mediate some behaviors, and modulate dopamine receptor D2-mediated events. They play a role in addiction by facilitating the gene expression changes that occur in the nucleus accumbens during addiction. They are Gs/a coupled and can stimulate neurons by indirectly activating cyclic AMP-dependent protein kinase.

Dopamine D1 Receptor Antagonists - Many typical and atypical antipsychotics are D1 receptor antagonists in addition to D2 receptor antagonists. No other D1 receptor antagonists have been approved for clinical use. Ecopipam is a selective D1-like receptor antagonist that has been studied clinically in humans in the treatment of a variety of conditions, including schizophrenia, cocaine abuse, obesity, pathological gambling, and Tourette's syndrome, with efficacy in some of these conditions seen. The drug produced mild-to-moderate, reversible depression and anxiety in clinical studies however and has yet to complete development for any indication.

Dopamine D1 Receptor Antagonists Emerging Drugs Chapters

This segment of the Dopamine D1 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dopamine D1 Receptor Antagonists Emerging Drugs

• Ecopipam (EBS-101): Emalex Biosciences

Ecopipam is an investigational first-in-class drug being evaluated in pediatric patients for the treatment of Tourette Syndrome (TS) and for childhood onset fluency disorder (Stuttering) in adults. Ecopipam selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor. Dopamine is a neurotransmitter in the central nervous system, and its receptors have been classified into two “families” based on their genetic structure: “D1” (including subtypes D1 and D5) and “D2” (including subtypes D2, D3, and D4). D1-receptor super-sensitivity may be a mechanism for the repetitive and compulsive behaviors associated with Tourette Syndrome. Currently approved therapies for the treatment of Tourette Syndrome act at D2 dopamine receptors. The drug is currently in phase 3 of clinical trials.

• Olanzapine (INP-105) : Impel Neuropharma

INP105 is a drug-device combination product being studied for the treatment of acute agitation associated with bipolar I disorder or schizophrenia. It is comprised of an intranasal formulation of olanzapine and Impel’s proprietary Precision Olfactory Delivery, or POD, nasal delivery device. The POD device delivers olanzapine to the richly-vascularized upper nasal cavity offering rapid, consistent and optimized bioavailability that can be administered by the patient or a caregiver. Olanzapine is the most commonly used treatment for acute agitation, but its use is limited to intramuscular injection. INP105 is intended to be suitable for use in the hospital emergency room setting as well as early in an episode where it could be self-administered in the patient’s home or supportive care setting. The drug is currently in phase 2 of clinical trials.

Further product details are provided in the report……..

Dopamine D1 Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Dopamine D1 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Dopamine D1 Receptor Antagonists

There are approx. 3+ key companies which are developing the Dopamine D1 Receptor Antagonists. The companies which have their Dopamine D1 Receptor Antagonists drug candidates in the most advanced stage, i.e. phase 3 include, Emalex Biosciences.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Dopamine D1 Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dopamine D1 Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine D1 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine D1 Receptor Antagonists drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine D1 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Dopamine D1 Receptor Antagonists.

Dopamine D1 Receptor Antagonists Report Insights

• Dopamine D1 Receptor Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dopamine D1 Receptor Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Dopamine D1 Receptor Antagonists drugs?
• How many Dopamine D1 Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Dopamine D1 Receptor Antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dopamine D1 Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dopamine D1 Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Emalex Biosciences
• Impel Neuropharma
• Starton Therapeutics
• Fabre-Kramer Pharmaceuticals
• Intra-Cellular Therapies

Key Products

• Ecopipam (EBS-101)
• INP-105
• STAR-OLZ
• FKF 02SC
• ITI 333